These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 25096079)

  • 1. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
    Okumura H; Ueyama M; Shoji S; English M
    J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
    Stranges PM; Hutton DW; Collins CD
    Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
    Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
    J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
    Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
    Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
    Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
    PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
    Rajasingham R; Enns EA; Khoruts A; Vaughn BP
    Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
    Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
    Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is fidaxomicin worth the cost? An economic analysis.
    Bartsch SM; Umscheid CA; Fishman N; Lee BY
    Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.